secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0000950170-25-012868
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTAB invalidates Atossa's US Patent 11,572,334; new patent 12,201,591 issued
----------------------------------------------------------------------------

- PTAB final decision found all claims of US Patent 11,572,334 unpatentable; Atossa will not appeal.
- Atossa issued new US Patent 12,201,591 (Sustained Release Compositions of Endoxifen) with 31 claims.
- Company states decision has no impact on current clinical formulations; will pursue continuation patent application.
- Patent estate now includes four issued US patents covering formulations in development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025012868/0000950170-25-012868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025012868/atos-20250130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-012868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer